Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations.

Mutagonda RF, Minzi OMS, Massawe SN, Asghar M, Färnert A, Kamuhabwa AAR, Aklillu E.

Drug Metab Dispos. 2019 Dec;47(12):1415-1424. doi: 10.1124/dmd.119.088062.

PMID:
31744845
2.

A decade since sulfonamide-based anti-malarial medicines were limited for intermittent preventive treatment of malaria among pregnant women in Tanzania.

Marealle AI, Mbwambo DP, Mikomangwa WP, Kilonzi M, Mlyuka HJ, Mutagonda RF.

Malar J. 2018 Nov 6;17(1):409. doi: 10.1186/s12936-018-2565-1.

3.

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.

Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, Färnert A, Aklillu E.

Malar J. 2017 Jul 3;16(1):267. doi: 10.1186/s12936-017-1914-9.

4.

Implementation of co-trimoxazole preventive therapy policy for malaria in HIV-infected pregnant women in the public health facilities in Tanzania.

Kamuhabwa AA, Gordian R, Mutagonda RF.

Drug Healthc Patient Saf. 2016 Dec 13;8:91-100. doi: 10.2147/DHPS.S119073. eCollection 2016.

5.

Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women.

Mutagonda RF, Kamuhabwa AA, Minzi OM, Massawe SN, Maganda BA, Aklillu E.

Malar J. 2016 May 13;15(1):278. doi: 10.1186/s12936-016-1327-1.

Supplemental Content

Loading ...
Support Center